# Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD

> **NCT02576626** · PHASE4 · COMPLETED · sponsor: **Wouter H. van Geffen** · enrollment: 40 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** indacaterol/glycopyrronium 110/50 Breezhaler®
- **DEVICE:** Placebo by Breezhaler®
- **DRUG:** ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation
- **DEVICE:** Placebo by nebulisation

## Key facts

- **NCT ID:** NCT02576626
- **Lead sponsor:** Wouter H. van Geffen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-09-29
- **Final completion:** 2017-09-29
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-10-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576626, "Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02576626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*